Roxithromycin vs cefaclor.
Hughes
T
T
Health Economics Research, Eli Lilly & Company, Indianapolis.
Scott
W G
WG
Scott
H M
HM
D002433:Cefaclor / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D015575:Roxithromycin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use